KINDSTAR GLOBALGENE TECHNOLOGY, INC. Kindstar Globalgene Technology, Inc. Stock
Equities
9960
KYG5262E1044
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 HKD | +2.56% |
|
+3.90% | -4.76% |
| Sales 2023 | 967M 133M 1.05B 182M | Sales 2024 * | 1.32B 182M 1.43B 249M | Capitalization | 1.41B 195M 1.52B 266M |
|---|---|---|---|---|---|
| Net income 2023 | 41M 5.66M 44.3M 7.74M | Net income 2024 * | 110M 15.18M 119M 20.75M | EV / Sales 2023 | 1.51 x |
| Net cash position 2023 * | - 0 0 0 | Net cash position 2024 * | - 0 0 0 | EV / Sales 2024 * | 1.07 x |
| P/E ratio 2023 |
35.9
x | P/E ratio 2024 * |
13.5
x | Employees | 3,125 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 53.13% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.56% | ||
| 1 week | +3.90% | ||
| Current month | +8.84% | ||
| 1 month | +13.48% | ||
| 3 months | +1.91% | ||
| 6 months | +7.38% | ||
| Current year | -4.76% |
1 week
1.48
1.60
1 month
1.411.60
Current year
1.381.79
1 year
1.381.86
3 years
1.389.78
5 years
1.389.78
10 years
1.389.78
| Managers | Title | Age | Since |
|---|---|---|---|
Shi Ang Huang
CEO | Chief Executive Officer | 66 | 11-02-21 |
Hai Jie Chai
DFI | Director of Finance/CFO | 46 | 20-12-03 |
Zan Bing Tu
COO | Chief Operating Officer | 52 | 20-12-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zuie Chin Huang
BRD | Director/Board Member | 58 | 12-01-29 |
Xin Ping Xia
BRD | Director/Board Member | 59 | 21-02-22 |
Shi Ang Huang
CEO | Chief Executive Officer | 66 | 11-02-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.6 | +2.56% | 728,500 |
| 24-04-25 | 1.56 | 0.00% | 94,000 |
| 24-04-24 | 1.56 | +1.30% | 221,000 |
| 24-04-23 | 1.54 | 0.00% | 412,500 |
| 24-04-22 | 1.54 | 0.00% | 997,189 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am
More quotes
Kindstar Globalgene Technology Inc is a China-based investment holding company principally engaged in the provision of clinical testing services. The Company operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctorsâ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.6
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.76% | 195M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- 9960 Stock
